Literature DB >> 17971366

Systemic lupus erythematosus in Saudi Arabia: morbidity and mortality in a multiethnic population.

T Heller1, M Ahmed, A Siddiqqi, C Wallrauch, S Bahlas.   

Abstract

The objective of this study is to summarize the features of patients with Lupus erythematosus in Saudi Arabia. Racial differences of patients and predictors of mortality are assessed. Ninety-three patients treated for SLE at the University Hospital in Jeddah were reviewed. Frequencies of clinical manifestations, causes of admission and causes of death were analysed. Variables predicting mortality were assessed by logistic regression and survival probabilities were estimated by the Kaplan-Meier method. The most frequent presenting symptoms were arthritis (68%) and fever (58%). Renal involvement was seen in 61% of patients. The majority of patients (61%) showed ANA titers higher than 1:1280. C4 levels were significantly lower in patients who died during the observation period than in survivors. The overall five-year survival rate was 92%. Variables predicting early death (<2 years after diagnosis) were young age at diagnosis, male sex and skin involvement. Death after more than two years correlated with older age at diagnosis and renal involvement. Patients of African descent had higher rates of neurological involvement and renal failure. The mortality in this group was highest, though this was not statistically significant. The overall survival in our cohort compares with mortality rates reported from western countries. However, renal disease tends to be common and has a severe prognosis, and thus merits additional attention.

Entities:  

Mesh:

Year:  2007        PMID: 17971366     DOI: 10.1177/0961203307081112

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

1.  Glomerulonephritis with crescents among adult Saudi patients outcome and its predictors.

Authors:  N Oudah; Z Al Duhailib; K Alsaad; S Qurashi; G Ghamdi; A Flaiw; F Hejaili; M Farooqui; A Al Sayyari
Journal:  Clin Exp Med       Date:  2011-06-26       Impact factor: 3.984

Review 2.  The global burden of SLE: prevalence, health disparities and socioeconomic impact.

Authors:  Erin E Carter; Susan G Barr; Ann E Clarke
Journal:  Nat Rev Rheumatol       Date:  2016-08-25       Impact factor: 20.543

3.  Patient-Reported Outcomes Predict Mortality in Lupus.

Authors:  Desiree R Azizoddin; Meenakshi Jolly; Shilpa Arora; Ed Yelin; Patricia Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-13       Impact factor: 4.794

4.  Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia.

Authors:  Abdurahman Saud Al Arfaj; Najma Khalil; Salman Al Saleh
Journal:  Rheumatol Int       Date:  2009-04-21       Impact factor: 2.631

5.  Clinical and laboratory manifestations of yemeni patients with systemic lupus erythematosus.

Authors:  Hassan A Al-Shamahy; Najla H M Dhaifallah; Yahya M Al-Ezzy
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

6.  In-hospital mortality in patients with systemic lupus erythematosus: a study from Jordan 2002-2017.

Authors:  Marwan H Adwan; Ula Qasem; Khader N Mustafa
Journal:  Rheumatol Int       Date:  2020-03-07       Impact factor: 2.631

7.  Neuropsychiatric lupus.

Authors:  Amal Alkhotani
Journal:  Sultan Qaboos Univ Med J       Date:  2013-02-27

8.  Clinical and Serologic Characteristics of Systemic Lupus Erythematosus in the Arab World: A Pooled Analysis of 3,273 Patients.

Authors:  Marwan Adwan
Journal:  Arch Rheumatol       Date:  2018-03-23       Impact factor: 1.472

9.  Pulmonary manifestations in systemic lupus erythematosus: association with disease activity.

Authors:  Omer S B Alamoudi; Suzan M Attar
Journal:  Respirology       Date:  2015-01-30       Impact factor: 6.424

10.  Awareness of systemic lupus erythematosus among primary health care patients in Riyadh, Saudi Arabia.

Authors:  Kholoud A Bin Haikel; Bader Al Tulaihi
Journal:  Saudi Med J       Date:  2019-02       Impact factor: 1.484

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.